PAZOPANIB BDBM31091
BDBM474107 Pazopanib metabolite M27 US10858364, Compound M27
cid_10113978 5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzene-1-sulfonamide GW-786034 JMC514632 Compound 13 BDBM26474 Pazopanib
- Jia, Y; Zhang, J; Feng, J; Xu, F; Pan, H; Xu, W Design, synthesis and biological evaluation of pazopanib derivatives as antitumor agents. Chem Biol Drug Des 83: 306-16 (2014)
- Qi, H; Chen, L; Liu, B; Wang, X; Long, L; Liu, D Synthesis and biological evaluation of novel pazopanib derivatives as antitumor agents. Bioorg Med Chem Lett 24: 1108-10 (2014)
- Zang, J; Liang, X; Huang, Y; Jia, Y; Li, X; Xu, W; Chou, CJ; Zhang, Y Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously. J Med Chem 61: 5304-5322 (2018)
- Harris, PA; Boloor, A; Cheung, M; Kumar, R; Crosby, RM; Davis-Ward, RG; Epperly, AH; Hinkle, KW; Hunter, RN; Johnson, JH; Knick, VB; Laudeman, CP; Luttrell, DK; Mook, RA; Nolte, RT; Rudolph, SK; Szewczyk, JR; Truesdale, AT; Veal, JM; Wang, L; Stafford, JA Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 51: 4632-40 (2008)